Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...

In January 2025, as part of its decision-making process, the EC asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in ...

28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

In January 2025, as part of its decision-making process, the EC asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its blockbuster cancer drug Tagrisso (osimertinib) for expanded use ...

Orphelia Pharma is exploring alternative regulatory pathways for Kizfizo (temozolomide) following a negative opinion from the ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...